Article: Physicochemical Characterization, in vitro Release and Permeation Studies of Respirable Rifampicin-Cyclodextrin Inclusion Complexes

The inclusion complexes of rifampicin with sucralose and beta-cyclodextrins were prepared by spray drying method. The complexes were characterized by size analyses, scanning electron microscopy, differential scanning calorimetry and x-ray diffraction methods. The results indicated the amorphous nature of resultant products. The solubility, in vitro release and skin permeation of the drug were enhanced after formation of inclusion complexes. The in vitro release and permeation of the inclusion complexes were greater in simulated lung fluid as compared to pure drug.

Citing Articles

An aerosol nanocomposite microparticle formulation using rifampicin-cyclodextrin inclusion complexes for the treatment of pulmonary diseases.

Freeman M, Shen J, Meenach S Int J Pharm. 2024; 665:124755.

PMID: 39321902 PMC: 11464167. DOI: 10.1016/j.ijpharm.2024.124755.

Physicochemical Stimuli-Mediated Precipitation Approach for the Modulation of Rifampicin's Dissolution and Oral Bioavailability.

Rai V, Pradhan D, Halder J, Rajwar T, Mahanty R, Saha I AAPS PharmSciTech. 2024; 25(7):189.

PMID: 39160328 DOI: 10.1208/s12249-024-02915-6.

Inclusion Complexes of Rifampicin with Native and Derivatized Cyclodextrins: Modeling, Formulation, and Characterization.

Anjani Q, Dominguez-Robles J, Utomo E, Font M, Martinez-Oharriz M, Permana A Pharmaceuticals (Basel). 2022; 15(1).

PMID: 35056077 PMC: 8781390. DOI: 10.3390/ph15010020.

Hepatoprotective agent tethered isoniazid for the treatment of drug-induced hepatotoxicity: Synthesis, biochemical and histopathological evaluation.

Singh C, Jodave L, Bhatt T, Gill M, Suresh S Toxicol Rep. 2017; 1:885-893.

PMID: 28962300 PMC: 5598226. DOI: 10.1016/j.toxrep.2014.10.001.

A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis.

Patil J, Devi V, Devi K, Sarasija S Lung India. 2015; 32(4):331-8.

PMID: 26180381 PMC: 4502196. DOI: 10.4103/0970-2113.159559.

References

1.

Qurrat-Ul-Ain , Sharma S, Khuller G, Garg S . Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother. 2003; 51(4):931-8. DOI: 10.1093/jac/dkg165. View

2.

Ahmad Z, Zahoor A, Sharma S, Khuller G . Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents. 2005; 26(4):298-303. DOI: 10.1016/j.ijantimicag.2005.07.012. View

3.

Baboota S, Dhaliwal M, Kohli K . Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. preparation and properties of rofecoxib hydroxypropyl beta-cyclodextrin inclusion complex: a technical note. AAPS PharmSciTech. 2005; 6(1):E83-90. PMC: 2750415. DOI: 10.1208/pt060114. View

4.

OHara P, Hickey A . Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res. 2000; 17(8):955-61. DOI: 10.1023/a:1007527204887. View

5.

Prabakaran D, Singh P, Jaganathan K, Vyas S . Osmotically regulated asymmetric capsular systems for simultaneous sustained delivery of anti-tubercular drugs. J Control Release. 2004; 95(2):239-48. DOI: 10.1016/j.jconrel.2003.11.013. View

Physicochemical Characterization, in Vitro Release and Permeation Studies of Respirable Rifampicin-Cyclodextrin Inclusion Complexes